15 years of revenue, profit, cash flow and balance-sheet history through FY2026, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2026 | $925M | $11M | 78.3% | 4.0% | $9M | — | $158M |
| 2024 | $855M | $42M | 81.1% | 7.8% | $51M | — | $182M |
| 2023 | $921M | $64M | 80.8% | 10.1% | $56M | — | $330M |
| 2022 | $999M | $69M | 80.6% | 10.8% | $94M | — | $288M |
| 2022 | $1.2B | $117M | 81.6% | 14.3% | $108M | — | $240M |
| 2021 | $1.1B | $125M | 81.6% | 15.6% | $145M | — | $312M |
| 2019 | $1.1B | $101M | 82.3% | 13.8% | $110M | — | $235M |
| 2018 | $1.2B | $126M | 83.1% | 15.8% | $141M | — | $214M |
| 2017 | — | $63M | — | — | $111M | — | $247M |
| 2016 | — | $100M | — | — | $104M | — | $176M |
| 2016 | — | $95M | — | — | $88M | — | $143M |
| 2015 | — | $77M | — | — | $85M | — | $111M |
| 2013 | — | $79M | — | — | $91M | — | $137M |
| 2012 | — | $66M | — | — | $84M | — | $71M |
| 2011 | — | $51M | — | — | $59M | — | $50M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Apr '26 | $250M | $8M | 76.2% | 5.5% | $7M | — | $163M |
| Jan '26 | $226M | -$2M | 78.2% | 1.7% | -$6M | — | $158M |
| Sep '25 | $214M | -$7M | 77.2% | 0.6% | -$5M | — | $145M |
| Jun '25 | $236M | $10M | 78.7% | 7.1% | $7M | — | $151M |
| Mar '25 | $250M | $9M | 79.0% | 6.3% | $13M | — | $180M |
| Dec '24 | $214M | $4M | 82.0% | 3.8% | $4M | — | $182M |
| Sep '24 | $200M | $11M | 80.4% | 7.8% | $27M | — | $365M |
| Jun '24 | $213M | $10M | 81.1% | 8.4% | $5M | — | $332M |
| Mar '24 | $228M | $17M | 81.1% | 10.8% | $14M | — | $328M |
| Dec '23 | $221M | $17M | 80.9% | 11.0% | $19M | — | $330M |
| Sep '23 | $213M | $11M | 80.1% | 8.3% | $21M | — | $307M |
| Jul '23 | $238M | $17M | 81.8% | 10.2% | $6M | — | $300M |
| Apr '23 | $248M | $18M | 80.5% | 10.8% | $11M | — | $295M |
| Dec '22 | $228M | $13M | 79.6% | 9.9% | $37M | — | $288M |
| Oct '22 | $233M | $15M | 80.0% | 9.7% | $26M | — | $247M |
| Jul '22 | $264M | $19M | 81.3% | 11.1% | $13M | — | $230M |
| Apr '22 | $273M | $22M | 81.2% | 12.1% | $18M | — | $238M |
| Jan '22 | $267M | $20M | 80.4% | 11.8% | $22M | — | $240M |
| Oct '21 | $274M | $27M | 81.5% | 14.9% | $31M | — | $249M |
| Jul '21 | $337M | $38M | 83.1% | 15.9% | $38M | — | $265M |
How the market has priced USNA against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, USANA HEALTH SCIENCES INC's revenue has declined 4.0% per year, and net income declined 38.7% per year. These are computed facts, not advice.
As of FY2026, USANA HEALTH SCIENCES INC reported — of total debt against $158M of cash; operating income covered interest expense 44×.
In FY2026, gross margin was 78.3%, operating margin 4.0%, and net margin 1.2%.
As of Jun '26, USANA HEALTH SCIENCES INC traded at a price-to-earnings ratio of about 33.9× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.